Strength in Amalgamation: Newer Combination Agents for HIV and Implications for Practice.

about

Strength in Amalgamation: Newer Combination Agents for HIV and Implications for Practice.

Item

http://www.wikidata.org/entity/Q45961010

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Strength in Amalgamation: Newer Combination Agents for HIV and Implications for Practice.

@en

Strength in Amalgamation: Newer Combination Agents for HIV and Implications for Practice.

@nl

type

Item

label

Strength in Amalgamation: Newer Combination Agents for HIV and Implications for Practice.

@en

Strength in Amalgamation: Newer Combination Agents for HIV and Implications for Practice.

@nl

prefLabel

Strength in Amalgamation: Newer Combination Agents for HIV and Implications for Practice.

@en

Strength in Amalgamation: Newer Combination Agents for HIV and Implications for Practice.

@nl

P1476

Strength in Amalgamation: Newer Combination Agents for HIV and Implications for Practice

@en

P2093

Christopher McCoy

http://www.w3.org/2001/XMLSchema#string

Daniel B Chastain

http://www.w3.org/2001/XMLSchema#string

Ethan Smith

http://www.w3.org/2001/XMLSchema#string

Melissa Badowski

http://www.w3.org/2001/XMLSchema#string

Rustin Crutchley

http://www.w3.org/2001/XMLSchema#string

Society of Infectious Diseases Pharmacists

http://www.w3.org/2001/XMLSchema#string

P2860

Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro

Prevention of HIV-1 infection with early antiretroviral therapy

The prevalence of transmitted resistance to first-generation non-nucleoside reverse transcriptase inhibitors and its potential economic impact in HIV-infected patients

Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data.

Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy

When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study.

Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study.

Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.

Adherence and HIV RNA Suppression in the Current Era of Highly Active Antiretroviral Therapy.

P304

86-107

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PHAR.2055

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Elizabeth M Sherman

P577

2017-12-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29105160

http://www.w3.org/2001/XMLSchema#string